It was shown that there is a connection between GPR6 and Parkinson’s disease (Laun & Song, 2017).
In human neuroblastoma cells, THC, but not CBD was shown to have neuroprotective properties. PPAR-gamma mediated this neuroprotection (Carroll et al., 2012).
In a rat model of Parkinson’s Disease, THCV and CBD showed neuroprotective properties in a CB2-independent way (García et al., 2011). Mobility was also shown to be improved by THCV in this study.
In cultured midbrain neurons, it was found that CBD, THCA, and THC exhibited anti-oxidative effects. Furthermore, THCA and THC were found to exert neuroprotective effects (Moldzio et al., 2012).
In one study, dopamine release was reduced by anandamide via TRPV1 receptors, (de Lago et al., 2004) proposing that they play a role in movement behavior.